Nautilus Biotechnology Reports Q1 2026 Financial Results and Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy NAUT?
Source: NASDAQ.COM
- Improved Financial Performance: Nautilus reported operating expenses of $16.1 million for Q1 2026, a 14% decrease from $18.8 million in the prior year, indicating effective cost control in salaries, benefits, and facilities, which enhances overall financial health.
- Reduced Net Loss: The company recorded a net loss of $14.7 million in Q1, down from $16.6 million a year earlier, reflecting positive outcomes in cost management and business advancement, potentially boosting investor confidence.
- Early Access Program Launch: Nautilus initiated the Iterative Mapping Early Access Program with Baylor College of Medicine as its first customer in an NIH-funded cancer study, which not only expands access to its validated Tau proteoform assay but also lays the groundwork for future commercialization.
- Strengthened Leadership Team: The appointment of Amber Faust as Vice President of Global Sales aims to drive the expansion of the Early Access program, strategically positioning the company to enhance market acceptance of the Voyager platform ahead of its commercial launch.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAUT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAUT
Wall Street analysts forecast NAUT stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.880
Low
2.50
Averages
2.50
High
2.50
Current: 2.880
Low
2.50
Averages
2.50
High
2.50
About NAUT
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nautilus Biotechnology Q1 2026 Earnings Call Insights
- Commercialization Progress: Nautilus plans to initiate commercial preorders by late 2026 and begin customer installations in early 2027, marking a significant step towards commercialization, although early customer engagements are not expected to drive immediate revenue.
- Financial Status: Operating expenses for Q1 were $16.1 million, with cash and cash equivalents totaling $143.4 million; despite a cash burn of $12.8 million, the company expects its runway to extend through 2027, indicating a degree of financial stability.
- Technical Validation: Nautilus's Tau assay in the service lab has passed verification, ensuring accuracy and stability, which lays the groundwork for processing customer samples and indicates significant progress in technical capabilities.
- Market Response: While analysts maintain a neutral stance on customer adoption visibility, management expresses confidence in execution and timelines, highlighting early collaboration with Baylor College of Medicine, suggesting growing market interest in its offerings.
See More
Nautilus Biotechnology Reports Q1 2026 Financial Results and Progress
- Improved Financial Performance: Nautilus reported operating expenses of $16.1 million for Q1 2026, a 14% decrease from $18.8 million in the prior year, indicating effective cost control in salaries, benefits, and facilities, which enhances overall financial health.
- Reduced Net Loss: The company recorded a net loss of $14.7 million in Q1, down from $16.6 million a year earlier, reflecting positive outcomes in cost management and business advancement, potentially boosting investor confidence.
- Early Access Program Launch: Nautilus initiated the Iterative Mapping Early Access Program with Baylor College of Medicine as its first customer in an NIH-funded cancer study, which not only expands access to its validated Tau proteoform assay but also lays the groundwork for future commercialization.
- Strengthened Leadership Team: The appointment of Amber Faust as Vice President of Global Sales aims to drive the expansion of the Early Access program, strategically positioning the company to enhance market acceptance of the Voyager platform ahead of its commercial launch.
See More
Nautilus Biotechnology Q1 Earnings Beat Expectations
- Earnings Beat: Nautilus Biotechnology reported a Q1 GAAP EPS of -$0.12, beating expectations by $0.02, indicating a slight improvement in financial performance that may boost investor confidence.
- Strong Cash Position: As of March 31, 2026, the company held $143.4 million in cash, cash equivalents, and investments, ensuring sufficient funding for future R&D and operations, thereby supporting its long-term strategic goals.
- Expense Growth Projection: Nautilus anticipates a 15%-20% increase in expenses for 2026, primarily due to the ramp-up of its early access program, which may impact short-term profitability but is expected to enhance long-term competitiveness in the market.
- Increased Market Attention: Following Nautilus's presentation at the TD Cowen 46th Annual Health Care Conference, market interest in its future developments and technological innovations has significantly increased, potentially leading to more investment opportunities for the company.
See More
Nautilus Biotechnology Q4 2025 Earnings Call Highlights
- Successful Product Launch: Nautilus unveiled the Voyager instrument at the US Human Proteome Organization Conference, receiving positive feedback that indicates strong interest from researchers in new protein measurement technologies, suggesting a growing market demand.
- Early Access Program Initiation: The company launched the Early Access Program for Iterative Mapping ahead of schedule, marking a transition from development to active customer engagement, which is expected to enhance customer relationships and drive future revenue growth.
- Improved Financial Performance: Total operating expenses for Q4 2025 were $15.4 million, a 23% decrease year-over-year, with cash burn at $50.2 million, down from 2024, demonstrating effective cost control and resource allocation.
- Optimistic Future Outlook: The company anticipates a 15%-20% increase in total operating expenses for 2026, with plans for primary revenue growth to begin in 2027, reflecting Nautilus's confidence in its commercialization strategy and market positioning.
See More
Nautilus Biotechnology Reports Q4 Earnings and 2026 Outlook
- Earnings Performance: Nautilus Biotechnology reported a Q4 GAAP EPS of -$0.11, beating expectations by $0.03, indicating initial success in cost control despite remaining in the red.
- Cash Position: As of December 31, 2025, the company had $156.1 million in cash, cash equivalents, and investments, reflecting a degree of financial stability that can support future operational needs in the current economic climate.
- 2026 Outlook: The company anticipates no material revenue from its Early Access Program engagements in 2026, while expecting operating expenses to rise by 15-20% year-over-year, which may pressure profitability.
- Sufficient Funding: Based on its cash reserves as of December 31, 2025, Nautilus Biotechnology believes it has adequate resources to fund operations through 2027, demonstrating confidence and foresight in its financial management.
See More
BETA Technologies Upgraded to Buy by Jefferies Amid Potential Catalysts
- Jefferies Upgrade: On February 11, 2026, Jefferies analyst Sheila Kahyaoglu upgraded BETA Technologies from Hold to Buy with a $30 price target, indicating that the shares are compelling at current levels following recent risk-off trading, suggesting potential for future gains.
- Amazon Investment Increase: As of December 31, 2025, Amazon acquired a $331.58 million position in BETA Technologies, making it one of its largest equity holdings, reflecting confidence in the electric aviation market and potentially providing financial support for BETA's future developments.
- Partnership Initiative: Surf Air Mobility announced a collaboration with the Hawaii Department of Transportation and BETA Technologies for the Electric Vertical Takeoff and Landing Integration Pilot Program, aiming to integrate airline operations with electric aircraft technology, which could enhance infrastructure development in Hawaii if selected.
- Electric Aviation Market Potential: BETA Technologies focuses on developing electric aircraft and propulsion systems, and as demand for sustainable aviation solutions grows, the company's technological innovations in the electric aviation sector are expected to drive significant future growth.
See More
Nautilus Biotechnology Q1 2026 Earnings Call Insights
- Commercialization Progress: Nautilus plans to initiate commercial preorders by late 2026 and begin customer installations in early 2027, marking a significant step towards commercialization, although early customer engagements are not expected to drive immediate revenue.
- Financial Status: Operating expenses for Q1 were $16.1 million, with cash and cash equivalents totaling $143.4 million; despite a cash burn of $12.8 million, the company expects its runway to extend through 2027, indicating a degree of financial stability.
- Technical Validation: Nautilus's Tau assay in the service lab has passed verification, ensuring accuracy and stability, which lays the groundwork for processing customer samples and indicates significant progress in technical capabilities.
- Market Response: While analysts maintain a neutral stance on customer adoption visibility, management expresses confidence in execution and timelines, highlighting early collaboration with Baylor College of Medicine, suggesting growing market interest in its offerings.
See More
Nautilus Biotechnology Reports Q1 2026 Financial Results and Progress
- Improved Financial Performance: Nautilus reported operating expenses of $16.1 million for Q1 2026, a 14% decrease from $18.8 million in the prior year, indicating effective cost control in salaries, benefits, and facilities, which enhances overall financial health.
- Reduced Net Loss: The company recorded a net loss of $14.7 million in Q1, down from $16.6 million a year earlier, reflecting positive outcomes in cost management and business advancement, potentially boosting investor confidence.
- Early Access Program Launch: Nautilus initiated the Iterative Mapping Early Access Program with Baylor College of Medicine as its first customer in an NIH-funded cancer study, which not only expands access to its validated Tau proteoform assay but also lays the groundwork for future commercialization.
- Strengthened Leadership Team: The appointment of Amber Faust as Vice President of Global Sales aims to drive the expansion of the Early Access program, strategically positioning the company to enhance market acceptance of the Voyager platform ahead of its commercial launch.
See More
Nautilus Biotechnology Q1 Earnings Beat Expectations
- Earnings Beat: Nautilus Biotechnology reported a Q1 GAAP EPS of -$0.12, beating expectations by $0.02, indicating a slight improvement in financial performance that may boost investor confidence.
- Strong Cash Position: As of March 31, 2026, the company held $143.4 million in cash, cash equivalents, and investments, ensuring sufficient funding for future R&D and operations, thereby supporting its long-term strategic goals.
- Expense Growth Projection: Nautilus anticipates a 15%-20% increase in expenses for 2026, primarily due to the ramp-up of its early access program, which may impact short-term profitability but is expected to enhance long-term competitiveness in the market.
- Increased Market Attention: Following Nautilus's presentation at the TD Cowen 46th Annual Health Care Conference, market interest in its future developments and technological innovations has significantly increased, potentially leading to more investment opportunities for the company.
See More
Nautilus Biotechnology Q4 2025 Earnings Call Highlights
- Successful Product Launch: Nautilus unveiled the Voyager instrument at the US Human Proteome Organization Conference, receiving positive feedback that indicates strong interest from researchers in new protein measurement technologies, suggesting a growing market demand.
- Early Access Program Initiation: The company launched the Early Access Program for Iterative Mapping ahead of schedule, marking a transition from development to active customer engagement, which is expected to enhance customer relationships and drive future revenue growth.
- Improved Financial Performance: Total operating expenses for Q4 2025 were $15.4 million, a 23% decrease year-over-year, with cash burn at $50.2 million, down from 2024, demonstrating effective cost control and resource allocation.
- Optimistic Future Outlook: The company anticipates a 15%-20% increase in total operating expenses for 2026, with plans for primary revenue growth to begin in 2027, reflecting Nautilus's confidence in its commercialization strategy and market positioning.
See More
Nautilus Biotechnology Reports Q4 Earnings and 2026 Outlook
- Earnings Performance: Nautilus Biotechnology reported a Q4 GAAP EPS of -$0.11, beating expectations by $0.03, indicating initial success in cost control despite remaining in the red.
- Cash Position: As of December 31, 2025, the company had $156.1 million in cash, cash equivalents, and investments, reflecting a degree of financial stability that can support future operational needs in the current economic climate.
- 2026 Outlook: The company anticipates no material revenue from its Early Access Program engagements in 2026, while expecting operating expenses to rise by 15-20% year-over-year, which may pressure profitability.
- Sufficient Funding: Based on its cash reserves as of December 31, 2025, Nautilus Biotechnology believes it has adequate resources to fund operations through 2027, demonstrating confidence and foresight in its financial management.
See More
BETA Technologies Upgraded to Buy by Jefferies Amid Potential Catalysts
- Jefferies Upgrade: On February 11, 2026, Jefferies analyst Sheila Kahyaoglu upgraded BETA Technologies from Hold to Buy with a $30 price target, indicating that the shares are compelling at current levels following recent risk-off trading, suggesting potential for future gains.
- Amazon Investment Increase: As of December 31, 2025, Amazon acquired a $331.58 million position in BETA Technologies, making it one of its largest equity holdings, reflecting confidence in the electric aviation market and potentially providing financial support for BETA's future developments.
- Partnership Initiative: Surf Air Mobility announced a collaboration with the Hawaii Department of Transportation and BETA Technologies for the Electric Vertical Takeoff and Landing Integration Pilot Program, aiming to integrate airline operations with electric aircraft technology, which could enhance infrastructure development in Hawaii if selected.
- Electric Aviation Market Potential: BETA Technologies focuses on developing electric aircraft and propulsion systems, and as demand for sustainable aviation solutions grows, the company's technological innovations in the electric aviation sector are expected to drive significant future growth.
See More
